{"id":702,"date":"2023-10-05T07:00:00","date_gmt":"2023-10-05T11:00:00","guid":{"rendered":"https:\/\/angany.com\/?p=702"},"modified":"2023-10-03T09:28:53","modified_gmt":"2023-10-03T13:28:53","slug":"angany-announces-first-in-human-clinical-study-on-ang-101-a-vaccine-candidate-to-treat-cat-allergy","status":"publish","type":"post","link":"https:\/\/angany.com\/angany-announces-first-in-human-clinical-study-on-ang-101-a-vaccine-candidate-to-treat-cat-allergy\/","title":{"rendered":"Angany announces First-in-Human Clinical Study on ANG-101, a Vaccine Candidate to Treat Cat Allergy"},"content":{"rendered":"\n

The Royal Brompton Hospital, in London, begins Clinical Trial of Angany\u2019s Vaccine Candidate to treat Cat Allergy.<\/strong><\/p>\n\n\n\n

Quebec City, Canada, <\/strong>October 3, 2023 <\/strong>\u2013 Angany Inc., announces that it has received clearance (Notice of Acceptance) from MHRA (Medicines and Healthcare Products Regulatory Agency) for the first clinical study to be conducted on its vaccine candidate ANG-101 to treat human allergy to cats. This clinical study is a First in Human, open label and single site evaluation of the safety, allergenicity and immunogenicity of the new vaccine in adult patients allergic to cat dander and will be conducted under the guidance of Professor Stephen Durham and Dr Guy Scadding, two leading clinical allergy experts from Imperial College London.<\/p>\n\n\n\n

A promising approach against cat allergy<\/h2>\n\n\n\n

There is currently no cure for cat allergy, which is a very common and life-long condition. Over-the-counter and prescription medications relieve patients of symptoms, but do not prevent allergy from progressing. The only disease-modifying treatment against allergy is desensitization, a form of allergen immunotherapy, which requires years of cat allergen administration and is associated with a poor success rate and the risk of allergic side effects.<\/p>\n\n\n\n

Angany\u2019s ANG-101 is a therapeutic vaccine that provides a disruptive disease-modifying approach for the treatment of cat allergy. Derived from its proprietary eBioparticle-Potentiated Immunotherapy\u2122 technology, ANG-101 active immunotherapeutic ingredient is a unique 140 nm enveloped bioparticle (eBioparticle\u2122) that mimics a virus in shape and size with its surface covered with thousands of copies of cat major allergen Fel d 1.<\/p>\n\n\n\n

Quotes<\/h2>\n\n\n\n

\u201cWe are very pleased that our new and promising approach to cat allergy immunotherapy is now being tested in patients, in a study that constitutes the first step of a comprehensive clinical development program. We have named this clinical study \u201cHOPE\u201d as this important milestone in Angany\u2019s vaccine development program should raise new hope for millions of people affected by allergy worldwide. ANG-101 is a first from a vaccine portfolio in development that aims to cover major allergies in humans and companion animals.\u201d<\/em><\/p>\n\n\n\n